Skip to main content
Careers Contact us
Exicure, Inc. Logo
  • Company
    • About Us
    • Management
    • Board of Directors
    • Advisory Board
  • Therapeutic Focus
    • Neurological Disorders
    • Chronic Pain
    • Hair Loss Disorders
  • Science and Technology
    • Exicure's Approach
    • References and Papers
  • Pipeline
    • Pipeline
    • Collaboration Programs
  • Partnering and Licensing
  • Investors
  • Investors
  • News
  • Events & Presentations
  • Stock Info
    • Stock Quote & Chart
    • Analyst Coverage
    • Form 8937
  • Financials
    • Interactive Financials
    • Financial Summary
    • SEC Filings
    • Annual Reports
  • Governance
    • Executive Management
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Resources
    • Contact IR
    • FAQs
    • Email Alerts

News

  • Company
    • About Us
    • Management
    • Board of Directors
    • Advisory Board
    • Scientific Team
  • Therapeutic Focus
    • Genetic Disorders
    • Oncology
  • Science and Technology
  • Pipeline
    • Pipeline
    • AST-008
    • XCUR-FXN
    • Collaboration Programs
    • Compassionate Use Policy
  • Partnering and Licensing
  • Investors
  • Investors
  • News
  • Events & Presentations
  • Stock Info
    • Stock Quote & Chart
    • Analyst Coverage
    • Form 8937
  • Financials
    • Interactive Financials
    • Financial Summary
    • SEC Filings
    • Annual Reports
  • Governance
    • Executive Management
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Resources
    • Contact IR
    • FAQs
    • Email Alerts
Normal
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
12/12/2016
Exicure Enters Into a Strategic Alliance with Purdue Pharma L.P.
10/11/2016
Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
Download PDF format download (opens in new window)
04/26/2016
Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
Download PDF format download (opens in new window)
02/12/2016
Exicure Co-Founder Awarded Prestigious Dan David Prize
Download PDF format download (opens in new window)

Quick Links

  • SEC Filings
  • Investor FAQs

Contact Us

MacDougall

Karen Sharma
781-235-3060
ksharma@macbiocom.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Exicure, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Exicure, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Unsubscribe

Email Alert Sign Up Confirmation

  • Twitter
  • Linkedin
  • Site Map
  • Privacy & Terms of Use
  • Copyright 2011-
Powered By Q4 Inc. 5.87.0.1 (opens in new window)